John P. Maxwell

756 total citations
23 papers, 409 citations indexed

About

John P. Maxwell is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, John P. Maxwell has authored 23 papers receiving a total of 409 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 8 papers in Oncology and 6 papers in Organic Chemistry. Recurrent topics in John P. Maxwell's work include Cancer-related gene regulation (10 papers), Synthesis and Catalytic Reactions (4 papers) and Hepatitis C virus research (4 papers). John P. Maxwell is often cited by papers focused on Cancer-related gene regulation (10 papers), Synthesis and Catalytic Reactions (4 papers) and Hepatitis C virus research (4 papers). John P. Maxwell collaborates with scholars based in United States and United Kingdom. John P. Maxwell's co-authors include Kevin M. Cottrell, Yu-Ping Luong, Kai Lin, Chao Lin, Cynthia A. Gates, Yunyi Wei, Robert B. Perni, B. Govinda Rao, Debra Brennan and Sue Ma and has published in prestigious journals such as Journal of Biological Chemistry, Cancer Research and Clinical Cancer Research.

In The Last Decade

John P. Maxwell

21 papers receiving 384 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John P. Maxwell United States	8	212	154	127	107	79	23	409
John Pichardo United States	15	205 1.0×	120 0.8×	163 1.3×	146 1.4×	153 1.9×	30	458
Marina Taliani Italy	7	246 1.2×	147 1.0×	115 0.9×	162 1.5×	41 0.5×	9	384
Monica Bisbocci Italy	7	222 1.0×	165 1.1×	106 0.8×	148 1.4×	30 0.4×	10	336
Immacolata Conte Italy	8	121 0.6×	82 0.5×	62 0.5×	96 0.9×	132 1.7×	10	282
Megan H. Powdrill Canada	10	187 0.9×	157 1.0×	165 1.3×	138 1.3×	42 0.5×	18	407
Kevin X. Chen United States	14	210 1.0×	112 0.7×	211 1.7×	163 1.5×	233 2.9×	23	562
Kenny Simmen Belgium	7	128 0.6×	96 0.6×	99 0.8×	99 0.9×	121 1.5×	8	327
Savina Malancona Italy	13	107 0.5×	75 0.5×	122 1.0×	101 0.9×	215 2.7×	21	413
Sandrine Vendeville France	11	135 0.6×	195 1.3×	184 1.4×	144 1.3×	174 2.2×	15	519
Kevin M. Cottrell United States	7	211 1.0×	153 1.0×	173 1.4×	102 1.0×	57 0.7×	21	413

Countries citing papers authored by John P. Maxwell

Since Specialization

Citations

This map shows the geographic impact of John P. Maxwell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John P. Maxwell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John P. Maxwell more than expected).

Fields of papers citing papers by John P. Maxwell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John P. Maxwell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John P. Maxwell. The network helps show where John P. Maxwell may publish in the future.

Co-authorship network of co-authors of John P. Maxwell

This figure shows the co-authorship network connecting the top 25 collaborators of John P. Maxwell. A scholar is included among the top collaborators of John P. Maxwell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John P. Maxwell. John P. Maxwell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Briggs, Kimberly J., Kevin M. Cottrell, Minjie Zhang, et al.. (2025). TNG908 is a brain-penetrant, MTA-cooperative PRMT5 inhibitor developed for the treatment of MTAP-deleted cancers. Translational Oncology. 52. 102264–102264. 6 indexed citations

Borcherding, Dana C., Yang Lyu, Anthony P.W. Yuen, et al.. (2025). MTA-Cooperative PRMT5 Inhibitors Are Efficacious in MTAP-Deleted Malignant Peripheral Nerve Sheath Tumor Models. Clinical Cancer Research. 31(22). 4779–4789.

Liang, Jianglin, Hongmin Li, Kevin M. Cottrell, et al.. (2025). Development of a Commercial Ready Process for TNG908: A Potent, Selective, and Brain-Penetrant MTA-Cooperative PRMT5 Inhibitor. Organic Process Research & Development. 29(3). 946–952.

Cottrell, Kevin M., Kimberly J. Briggs, Alice Tsai, et al.. (2025). Discovery of TNG462: A Highly Potent and Selective MTA-Cooperative PRMT5 Inhibitor to Target Cancers with MTAP Deletion. Journal of Medicinal Chemistry. 68(5). 5097–5119. 7 indexed citations

Cottrell, Kevin M., Douglas A. Whittington, Kimberly J. Briggs, et al.. (2025). MTA-Cooperative PRMT5 Inhibitors: Mechanism Switching Through Structure-Based Design. Journal of Medicinal Chemistry. 68(4). 4217–4236. 3 indexed citations

Simoneau, Antoine, Hsin‐Jung Wu, Charlotte Pratt, et al.. (2024). Abstract 4527: TNG348 is synergistic with PARP inhibitors in tumor models with elevated replication stress. Cancer Research. 84(6_Supplement). 4527–4527. 1 indexed citations

Cottrell, Kevin M., Kimberly J. Briggs, Douglas A. Whittington, et al.. (2024). Discovery of TNG908: A Selective, Brain Penetrant, MTA-Cooperative PRMT5 Inhibitor That Is Synthetically Lethal with MTAP-Deleted Cancers. Journal of Medicinal Chemistry. 67(8). 6064–6080. 34 indexed citations

Borcherding, Dana C., Xiaochun Zhang, Minjie Zhang, et al.. (2023). EXTH-63. MTA-COOPERATIVE PRMT5 INHIBITORS ARE EFFICACIOUS IN MTAP-DELETED MALIGNANT PERIPHERAL NERVE SHEATH TUMOR MODELS. Neuro-Oncology. 25(Supplement_5). v238–v238. 3 indexed citations

Simoneau, Antoine, Charlotte Pratt, Hsin‐Jung Wu, et al.. (2023). Abstract B054: TNG348, a selective USP1 inhibitor, shows strong preclinical combination activity with PARP inhibitors and other agents targeting DNA repair. Molecular Cancer Therapeutics. 22(12_Supplement). B054–B054. 5 indexed citations

10.

Zhang, Minjie, Kevin M. Cottrell, Brian B. Haines, et al.. (2023). Abstract 3452: TNG908, a brain-penetrant MTA-cooperative PRMT5 inhibitor, is efficacious in preclinical glioblastoma models. Cancer Research. 83(7_Supplement). 3452–3452. 3 indexed citations

11.

Briggs, Karen K., Erik Wilker, Charles B. Davis, et al.. (2022). 24P Evidence for synergy between TNG908, an MTAPnull-selective PRMT5 inhibitor, and sotorasib in an MTAPnull/KRASG12C xenograft model. Annals of Oncology. 33. S12–S12. 3 indexed citations

12.

Briggs, Kimberly J., Kevin M. Cottrell, Erik Wilker, et al.. (2022). Abstract 3941: TNG908 is an MTAPnull-selective PRMT5 inhibitor that drives tumor regressions in MTAP-deleted xenograft models across multiple histologies. Cancer Research. 82(12_Supplement). 3941–3941. 5 indexed citations

13.

Newsome, David, Daigo Takemoto, Shawn Hillier, et al.. (2017). Abstract P5-06-05: Preclinical characterization of VX-984, a selective DNA-dependent protein kinase (DNA-PK) inhibitor in combination with doxorubicin in breast and ovarian cancers. Cancer Research. 77(4_Supplement). P5–6. 5 indexed citations

14.

Hillier, Shawn, David Newsome, Daigo Takemoto, et al.. (2016). Preclinical characterization of the selective DNA-dependent protein kinase (DNA-PK) inhibitor VX-984 in combination with chemotherapy. Annals of Oncology. 27. vi122–vi122. 4 indexed citations

15.

Boucher, Diane M., Russell R. Hoover, Yuxin Wang, et al.. (2016). Abstract 3716: Potent radiation enhancement with VX-984, a selective DNA-PKcs inhibitor for the treatment of NSCLC. Cancer Research. 76(14_Supplement). 3716–3716. 5 indexed citations

16.

Perni, Robert B., Gurudatt Chandorkar, Kevin M. Cottrell, et al.. (2007). Inhibitors of hepatitis C virus NS3·4A protease. Effect of P4 capping groups on inhibitory potency and pharmacokinetics. Bioorganic & Medicinal Chemistry Letters. 17(12). 3406–3411. 16 indexed citations

17.

Lin, Chao, Kai Lin, Yu-Ping Luong, et al.. (2004). In Vitro Resistance Studies of Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061. Journal of Biological Chemistry. 279(17). 17508–17514. 228 indexed citations

18.

Posner, Gary H., John P. Maxwell, & Mehmet Kahraman. (2003). Mild, Fast, and Stereoselective Epoxide Opening by Ketone Enolate Anions. Application to Synthesis of the Norlignan Curculigine. The Journal of Organic Chemistry. 68(8). 3049–3054. 24 indexed citations

19.

Posner, Gary H., John P. Maxwell, Hardwin O’Dowd, et al.. (2000). Antimalarial sulfide, sulfone, and sulfonamide trioxanes. Bioorganic & Medicinal Chemistry. 8(6). 1361–1370. 31 indexed citations

20.

Maxwell, John P., et al.. (1974). Behaviour of an aziridine alkylating agent in acid solution. Biochemical Pharmacology. 23(1). 168–170. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact